HealthCare Royalty Partners is a royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. self-described.

HealthCare Royalty Partners

HealthCare Royalty | 1,961 followers on LinkedIn. Advancing Biopharmaceutical Innovation with Creative Capital Solutions | HealthCare Royalty (&quot;HCRx&quot;) is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. HCRx has invested $5+ billion in more than 85 biopharma products since inception and has offices in Stamford (CT), San Francisco, Boston and London.  The HCRx team consists of 33 individuals (including our Senior Advisors), including former pharmaceutical executives, scientists, physicians, bankers, research analysts and consultants.

Frank Armstrong

Chief Scientific Officer at HealthCare Royalty

Shin Kang

Chief Executive Officer at Memgen

Greg Brown

Chief Medical Officer at HealthCare Royalty

Warren Cooper

HealthCare Royalty

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics https://lnkd.in/e2tjDbq7

Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million

Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments

We are thrilled to share insights from the recent roundtable discussion hosted by DNB and Back Bay Life Science Advisors. On May 7th, 2024, industry leaders Clarke Futch, Chairman and CEO of HealthCare Royalty (HCRx), and Chris Posner, President and CEO of Cara Therapeutics, engaged in a thought-provoking discussion on alternative financing in healthcare. Moderated by Jonathan Gertler of Back Bay Life Science Advisors, the forum also featured Anne Grabe, Global Head of Healthcare Banking, DNB, and Patrik Ling, Senior Analyst, DNB. This diverse group of experts delved into innovative financing strategies that are shaping the future of healthcare.

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

Zevra Therapeutics Refinances Existing Debt With Up To $100M In Committed Capital Under New Credit Facility

Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million https://lnkd.in/ef5Ar6EC

Thank you to everyone who joined us in the Dominican Republic at our 14th Annual Senior Advisor Board Offsite. Lots of interesting and insightful sessions in a beautiful setting.

Liquidia Corporation Announces $100 Million in New Financings https://lnkd.in/ez-rBm6z

Domain Not Resolving

DNSSEC

IPv6

Gravatar Profiles

Fastly Hosted

Fastly

Fastly Load Balancer

Varnish

Akamai Hosted

Perl

Chairman & Chief Executive Officer

Clarke Futch

Owner

Roger Benkarski

Chief Financial Officer

Thomas Conner

Account Manager

Karen DeLoney

Principal, Chief Legal Officer

Andrew Reardon

President

Caleb Ward

Managing Director and Head of Investor Relations

Carlos Almodóvar

Vice President

Collin Stewart

Chief Executive Officer

Grant Eidson

Partner

John Urquhart

Louis Berneman

Clarke B. Futch

Paul J Hadden

Senior Managing Director

Timothy Bryant

General Counsel

Warren D. Cooper

Partner and Chief Medical Officer

Gregory B. Brown, MD

Founding Managing Director

Christopher White

President and Chief Financial Officer

Thomas K. Conner

Chief Accounting Officer and Treasurer

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics

Zevra Therapeutics is a biopharmaceutical company focused on discovering and developing therapies for pain, ADHD, and other CNS diseases.

TG Therapeutics, a biopharmaceutical company, develops agents for the treatment of hematologic malignancies and autoimmune disorders.

Acufocus is a medical device company that develops and markets KAMRA inlay for the treatment of near vision loss.

Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.

Opko Health engages in the discovery and development of novel and proprietary technologies for pharmaceuticals and diagnostics.

Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.

Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders.

TearScience develops devices that provide significant clinical identification and treatment of evaporative dry eye.

Cara Therapeutics is a biotechnology company focused on developing therapeutics to treat diseases associated with pain and inflammation.

Investors Active in Pennsylvania

Private Equity Firms with Investments in San Francisco Bay Area

Private Equity Firms with Investments in Greater Atlanta Area

Investors Active in United States (Top 10K)

We are a $3.0+ billion global healthcare investment firm. We invest primarily in commercial stage healthcare product assets that have significant clinical value, strong barriers to entry and that are marketed by some of the world’s largest pharmaceutical companies. Over the past decade, our senior investment team has completed more than 60 royalty investments valued in excess of $2.5 billion. For more information, visit www.healthcareroyalty.com.

news impact assignment basic	general
public peers	general	Nov 15, 2024 5:11 PM	3e894f60
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 15, 2024 5:11 PM	e4ac34ff
crunchbase trigger	general	Nov 15, 2024 5:11 PM	d40cf2ec
crunchbase profile	general	Nov 15, 2024 9:16 PM	d79ae165
li profile	general	Nov 15, 2024 5:11 PM	10b84b4c
translate crunchbase fundingrounds	general	Nov 15, 2024 9:36 PM	7b361fd9
peers	general	Nov 15, 2024 5:11 PM	d95fc8c1
news basic	general	Nov 15, 2024 5:11 PM	99b5a2d3
bundesanzeiger	filings
financials download nd	financials
private financials	financials

HCRX

COM:HCRX

HealthCare Royalty Partners